Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia

Stephanie C. Wu, James S. Wrobel, David G Armstrong

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Chronic, neuropathic pain may be secondary to myriad etiologies including diabetic peripheral neuropathy and fibromyalgia. It is a debilitating condition that imposes a significant burden on individuals and society alike. This article will review various instruments designed to assess quality of life (QoL) and key data assessing QoL of patients suffering from these diseases as well as currently available pharmacologic agents for symptomatic management. As basic and clinical science progress over the next few years, along with the introduction of novel pharmacologic agents, we anticipate greater potential for pain intervention and improvement in the quality of life of our patients.

Original languageEnglish (US)
JournalPain Medicine
Volume8
Issue numberSUPPL. 2
DOIs
StatePublished - Sep 2007
Externally publishedYes

Fingerprint

Fibromyalgia
Neuralgia
Quality of Life
Diabetic Neuropathies
Peripheral Nervous System Diseases
Chronic Pain
Pain

Keywords

  • Diabetes
  • Fibromyalgia
  • Foot
  • Neuropathy
  • Pain
  • Quality of Life
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia. / Wu, Stephanie C.; Wrobel, James S.; Armstrong, David G.

In: Pain Medicine, Vol. 8, No. SUPPL. 2, 09.2007.

Research output: Contribution to journalArticle

@article{9d0773f1529244dc929d186b9f124a79,
title = "Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia",
abstract = "Chronic, neuropathic pain may be secondary to myriad etiologies including diabetic peripheral neuropathy and fibromyalgia. It is a debilitating condition that imposes a significant burden on individuals and society alike. This article will review various instruments designed to assess quality of life (QoL) and key data assessing QoL of patients suffering from these diseases as well as currently available pharmacologic agents for symptomatic management. As basic and clinical science progress over the next few years, along with the introduction of novel pharmacologic agents, we anticipate greater potential for pain intervention and improvement in the quality of life of our patients.",
keywords = "Diabetes, Fibromyalgia, Foot, Neuropathy, Pain, Quality of Life, Treatment",
author = "Wu, {Stephanie C.} and Wrobel, {James S.} and Armstrong, {David G}",
year = "2007",
month = "9",
doi = "10.1111/j.1526-4637.2007.00350.x",
language = "English (US)",
volume = "8",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia

AU - Wu, Stephanie C.

AU - Wrobel, James S.

AU - Armstrong, David G

PY - 2007/9

Y1 - 2007/9

N2 - Chronic, neuropathic pain may be secondary to myriad etiologies including diabetic peripheral neuropathy and fibromyalgia. It is a debilitating condition that imposes a significant burden on individuals and society alike. This article will review various instruments designed to assess quality of life (QoL) and key data assessing QoL of patients suffering from these diseases as well as currently available pharmacologic agents for symptomatic management. As basic and clinical science progress over the next few years, along with the introduction of novel pharmacologic agents, we anticipate greater potential for pain intervention and improvement in the quality of life of our patients.

AB - Chronic, neuropathic pain may be secondary to myriad etiologies including diabetic peripheral neuropathy and fibromyalgia. It is a debilitating condition that imposes a significant burden on individuals and society alike. This article will review various instruments designed to assess quality of life (QoL) and key data assessing QoL of patients suffering from these diseases as well as currently available pharmacologic agents for symptomatic management. As basic and clinical science progress over the next few years, along with the introduction of novel pharmacologic agents, we anticipate greater potential for pain intervention and improvement in the quality of life of our patients.

KW - Diabetes

KW - Fibromyalgia

KW - Foot

KW - Neuropathy

KW - Pain

KW - Quality of Life

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=34548087307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548087307&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4637.2007.00350.x

DO - 10.1111/j.1526-4637.2007.00350.x

M3 - Article

VL - 8

JO - Pain Medicine

JF - Pain Medicine

SN - 1526-2375

IS - SUPPL. 2

ER -